TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 346049

Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg orally for 2 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisone with aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with aspirin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 12
Study: 31442303

Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention (WLI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 32
Study: 31753045

Group type: EXPERIMENTAL
Intervention: Biomedical messages (BMM)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Recommended messages (RCM)
Number of subjects: 179
Study: 29354177

Group type: EXPERIMENTAL
Intervention: Standardized tomato extract (STE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 65
Study: 25941197

Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture (No. 2 braided nonabsorbable polyethylene terephthalate sutures)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Absorbable suture (braided absorbable polyglactin sutures)
Number of subjects: 48
Study: 23876833

Group type: EXPERIMENTAL
Intervention: Imatinib continuation (arm A, n=18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Imatinib discontinuation (arm B, n=15)
Number of subjects: 33
Study: 21707137

Group type: EXPERIMENTAL
Intervention: Family group cognitive-behavioral (FGCB) intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Written information comparison condition
Number of subjects: 111
Study: 19505878

Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg subcutaneously once daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 16703633

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic use
Number of subjects: 6
Study: 12956886

Group type: EXPERIMENTAL
Intervention: Strain Rate Imaging in patients with acute myocardial infarction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Strain Rate Imaging in normal subjects
Number of subjects: 12

Group type: COMPARATOR
Intervention: Peak systolic strain rate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mid systolic strain rate and end systolic strain
Number of subjects: 12
Study: 11103192

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with midazolam and ketamine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with alfentanil and etomidate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia regimens (TIVA) with propofol (in combination with alfentanil or ketamine)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Addition of 50% nitrous oxide
Number of subjects: 33
Study: 8922801

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg p.o. t.i.d.)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 182
Study: 1303075

Group type: EXPERIMENTAL
Intervention: 10% w/w tea tree oil cream
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 1% tolnaftate cream
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 104
Study: 3989740

Group type: EXPERIMENTAL
Intervention: Cooperative learning experiences
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individualistic learning experiences
Number of subjects: 30
Study: 28677942

Group type: EXPERIMENTAL
Intervention: Mulligan's fibular repositioning taping
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 16
Study: 27271264

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (n=15; 54±2 years)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n=15; 49±2 years)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 24048675

Group type: EXPERIMENTAL
Intervention: Company size >100
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Conflicts with the supervisor
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Having >1 chronic diseases
Number of subjects: 158
Study: 22360645

Group type: EXPERIMENTAL
Intervention: Low-flux dialyzers (polysulfone or triacetate) used in 4-hour hemodialysis sessions
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Model 1 for predicting total phosphate removal
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Model 2 for predicting total phosphate removal (noninvasive)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 165
Study: 20075849

Group type: EXPERIMENTAL
Intervention: Lactotripeptides (LTP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex+placebo)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Exercise and LTP (Ex+LTP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18707986

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg a day
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg a day
Number of subjects: 25620

Group type: EXPERIMENTAL
Intervention: Combination therapy (ramipril + telmisartan)
Number of subjects: 25620
Study: 16393331

Group type: EXPERIMENTAL
Intervention: rMal d 1mut
Number of subjects: 14
Study: 15758247

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d for 4 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 64
Study: 11422263

Group type: EXPERIMENTAL
Intervention: Imidazolidinyl urea (IMID) patch test at concentrations from 0 to 600 microg/cm(2)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Diazolidinyl urea (DU) patch test at concentrations from 0 to 600 microg/cm(2)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Formaldehyde patch test at 180 microg/cm(2)
Number of subjects: 181
Study: 9404698

Group type: EXPERIMENTAL
Intervention: CAV-E (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, etoposide 100 mg/m2)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CAV-T (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, teniposide 60 mg/m2)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CAV-E
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CAV-T
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: IFN-alpha (recombinant interferon-alpha-2b, 3 M.U., once a day for 9 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 140
Study: 8487648

Group type: EXPERIMENTAL
Intervention: Acipimox (500-mg capsules)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3552921

Group type: EXPERIMENTAL
Intervention: Propranolol (24 to 480 mg per day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg long-acting per day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31076857

Group type: EXPERIMENTAL
Intervention: Genetically determined 25(OH)D for risk of type 2 diabetes
Number of subjects: 10655

Group type: EXPERIMENTAL
Intervention: Genetically determined 25(OH)D for risk of prediabetes
Number of subjects: 10655

Group type: EXPERIMENTAL
Intervention: Genetically determined diabetes for 25(OH)D
Number of subjects: 10655

Group type: EXPERIMENTAL
Intervention: Genetically determined prediabetes for 25(OH)D
Number of subjects: 10655
Study: 30314383

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 27544805

Group type: EXPERIMENTAL
Intervention: High protein preload (40% protein, 0.4 CHO:fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High protein preload (40% protein, 3.6 CHO:fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glutamate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Valine, leucine, isoleucine, lysine, α‐aminobutyric acid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall amino acid profiles
Number of subjects: 36
Study: 25025926

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 63

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 63
Study: 21862334

Group type: EXPERIMENTAL
Intervention: Mid-vastus (MV) approach
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Medial parapatellar (PP) approach
Number of subjects: 1040
Study: 20385929

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of apelin‐36
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Systemic infusions of (Pyr(1))apelin‐13 (30 to 300 nmol/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 50

Group type: COMPARATOR
Intervention: (Pyr(1))apelin‐13
Number of subjects: 50
Study: 17551726

Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock wave treatment (ESWT; 1,500 shocks at 18 kV, 0.22 mJ/mm(2) without local anaesthesia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Percutaneous tenotomy of the common extensor origin
Number of subjects: 56
Study: 16899517

Group type: EXPERIMENTAL
Intervention: Cyclosporine-based immunosuppressive regimen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive regimen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Not treating subclinical acute rejection (SAR)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Controlled individualized calcineurin inhibitor exposure
Number of subjects: 126
Study: 14986815

Group type: EXPERIMENTAL
Intervention: Low daily doses of IFN‐alpha2b (1.5 MU) 'consolidation therapy' for 1 year
Number of subjects: 236

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 236
Study: 10986437

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8799660

Group type: EXPERIMENTAL
Intervention: Moderate level physical activity
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: High level physical activity
Number of subjects: 666

Group type: COMPARATOR
Intervention: Low-level physical activity (reference group)
Number of subjects: 666
Study: 1601137

Group type: EXPERIMENTAL
Intervention: Dalkon Shield (IUD)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Case-control and cohort studies
Number of subjects: 71
Study: 2413519

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories, 50 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin and Placebo
Number of subjects: 30
Study: 31372803

Group type: EXPERIMENTAL
Intervention: High-load resistance training (n=14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-load resistance training (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-exercising control group (n=16)
Number of subjects: 45
Study: 30328984

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Public intensive care units
Number of subjects: 124

Group type: COMPARATOR
Intervention: Private intensive care units
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: General approach to renal replacement therapy
Number of subjects: 124
Study: 27251406

Group type: EXPERIMENTAL
Intervention: Interval cycling (INT, 4 × 30 s maximal sprints interspersed by 4 min passive recovery)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous cycling (CON, 2 min continuous maximal sprint)
Number of subjects: 8
Study: 25549483

Group type: EXPERIMENTAL
Intervention: Infusion therapy with reamberinum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infusion therapy with modified gelatin (Gelofusin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infusion therapy with sodium chloride 0.9%
Number of subjects: 60

Group type: COMPARATOR
Intervention: No infusion therapy
Number of subjects: 60
Study: 23359968

Group type: EXPERIMENTAL
Intervention: UDCA and Fuzheng Huayu Capsule (FHC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 80
Study: 20407369

Group type: EXPERIMENTAL
Intervention: OMRON RX-I (wrist monitor) with hand positioned on the opposite shoulder
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: OMRON RX-I (wrist monitor) with hand positioned on the opposite elbow
Number of subjects: 200

Group type: COMPARATOR
Intervention: OMRON M4-I (arm monitor, gold standard)
Number of subjects: 200
Study: 18991514

Group type: EXPERIMENTAL
Intervention: Nigella sativa seed aqueous extract (0.375 mL/kg of 50 g% boiled extract)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study: 16055807

Group type: EXPERIMENTAL
Intervention: Comprehensive cognitive-behavioural therapy for patients in the early initial prodromal state
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptic amisulpride for patients in the late initial prodromal state
Number of subjects: 188

Group type: COMPARATOR
Intervention: Clinical management (control condition)
Number of subjects: 188
Study: 12452756

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroids alone
Number of subjects: 0
Study: 10027654

Group type: EXPERIMENTAL
Intervention: GHB 12.5 mg x kg(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHB 25 mg x kg(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.03 mg x kg(‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7585492

Group type: EXPERIMENTAL
Intervention: Standard care personnel providing information
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Verbal communication from the physician
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Written material
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nurses as an information source
Number of subjects: 83
Study: 2265765

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7442534

Group type: EXPERIMENTAL
Intervention: Strenuous physical exertion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Less strenuous physical exertion
Number of subjects: 35
Study: 30852021

Group type: EXPERIMENTAL
Intervention: Moderate space allowance (MOD; 1.85 m2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Maximized space allowance (MAX; 3.71 m2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional space allowance (CONV; 1.23 m2)
Number of subjects: 54
Study: 28384521

Group type: COMPARATOR
Intervention: Hydroxyapatite scaffold (Group B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite granules (Group C)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Spontaneous healing (Group A)
Number of subjects: 26
Study: 26327116

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus laser combination therapy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 303
Study: 24138699

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for CT and NG infection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Current diagnostic guidelines
Number of subjects: 12
Study: 21443536

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily Practice Composite Score (DP-6)
Number of subjects: 0
Study: 19733712

Group type: COMPARATOR
Intervention: Full drug-eluting stenting (full DES)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Spot drug-eluting stenting (spot DES)
Number of subjects: 179
Study: 17762645

Group type: EXPERIMENTAL
Intervention: Derivation group (generalized transfer function)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Validation group (generalized transfer function)
Number of subjects: 93
Study: 14752469

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected images
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Noncorrected images
Number of subjects: 102
Study: 11502527

Group type: EXPERIMENTAL
Intervention: Clinafloxacin 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinafloxacin 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study: 10762102

Group type: EXPERIMENTAL
Intervention: Positive group (focused on positive issues about bone density screening)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Negative group (focused on negative issues about bone density screening)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All-focusing group (focused on both positive and negative issues)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (focused on issues relating to the common cold)
Number of subjects: 90
Study: 8777381

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) low-dose regimen starting with 45 mg/day, lowering dose thereafter
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) 60 mg/day + levothyroxine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) 30 mg/day + levothyroxine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All MMI regimens
Number of subjects: 32
Study: 1853688

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1.5 mg.ml‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine 1 mg.kg‐1
Number of subjects: 60
Study: 6346833

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30039192

Group type: EXPERIMENTAL
Intervention: Immediate intervention condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed intervention condition
Number of subjects: 80
Study: 29429253

Group type: EXPERIMENTAL
Intervention: Serum free DNA hTERT content in spinal cord injury patients (experimental group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Disease control group (spinal fractures)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Negative control group (healthy volunteers)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Protein content of TERT in spinal cord injury patients (experimental group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Surface evoked potential (SEP) detection in spinal cord injury patients (experimental group)
Number of subjects: 46
Study: 27123743

Group type: EXPERIMENTAL
Intervention: HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) administered in 3 doses according to a 0, 1, 6 months schedule.
Number of subjects: 674
Study: 24669794

Group type: EXPERIMENTAL
Intervention: Pramipexole (dopamine D2-like receptor agonist) during sleep
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22682949

Group type: EXPERIMENTAL
Intervention: Sitagliptin + Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 20027029

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17564327

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 15742005

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for up to 4 years
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 1457
Study: 12438988

Group type: EXPERIMENTAL
Intervention: Spinal manipulation combined with low-tech rehabilitative exercise
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: MedX rehabilitative exercise
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Spinal manipulation alone
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Two exercise groups (spinal manipulation combined with low-tech rehabilitative exercise and MedX rehabilitative exercise)
Number of subjects: 191
Study: 10064664

Group type: EXPERIMENTAL
Intervention: Slow feed advancement (15 cc/kg/d increments, 10-day schedule to full feeds)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Fast feed advancement (35 cc/kg/d increments, 5-day schedule to full feeds)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Slow feed advancement
Number of subjects: 185

Group type: COMPARATOR
Intervention: Fast feed advancement
Number of subjects: 185
Study: 7743796

Group type: EXPERIMENTAL
Intervention: Tetracycline administration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Meibomian gland expression therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ocular rosacea patients (n = 28)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dermatologic rosacea patients (n = 15)
Number of subjects: 43
Study: 2225367

Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 780

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study: 30638154

Group type: EXPERIMENTAL
Intervention: High-intensity resistance circuit-based training in hypoxia (HRChyp)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-intensity resistance circuit-based training in normoxia (HRCnorm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both HRChyp and HRCnorm
Number of subjects: 28
Study: 29529231

Group type: EXPERIMENTAL
Intervention: Early progressive feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed progressive feeding (control)
Number of subjects: 60
Study: 26895326

Group type: EXPERIMENTAL
Intervention: Microsurgical free vascularized lymph node transfer (LNT) followed by 6 months of physiotherapy and compression
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiotherapy and compression alone for 6 months
Number of subjects: 36
Study: 25296066

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 284